Company intelligence / Profile preview
Microbio Co., Ltd.
Taipei, Taiwantwmicrobio.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Microbio has developed multiple innovative medicines and medical products. Several products have received regulatory approval in Taiwan and China, including treatments for neoplasms and diabetic foot ulcers. The company also has late-stage clinical assets targeting atopic dermatitis, primary dysmenorrhea, and hepatocellular carcinoma.
- Therapeutic areas
- Women's HealthOncologyEndocrinologyDermatology
- Modalities
- Monoclonal antibodiesSmall molecule drugssiRNA therapeuticsMicrobiota-based therapiesChemical drugs
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
Beyond the preview
Go deeper on Microbio Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Microbio Co., Ltd..